a4294m
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca
$360m Irish manufacturing investment
21 September 2021 07:00 BST
AstraZeneca to invest $360m in advanced manufacturing facility in
Ireland
Investment will transform development and commercialisation of new
medicines
AstraZeneca is planning on establishing a next-generation active
pharmaceutical ingredient (API) manufacturing facility for small
molecules near Dublin, Ireland to ensure the Company's global
supply network is fit for future growth.
The new plant will allow for late-stage development and early
commercial supply, adopting state of the art process technology and
digital innovation that is designed to meet the needs of the
Company's new medicines pipeline with speed and
agility.
The $360m planned investment at the Alexion Campus in College
Park, Dublin, is expected to create about 100 highly skilled direct
jobs, including scientists and engineers, and further indirect
jobs. The project, which will provide an important boost to the
local economy and to the country's life-sciences sector, was
developed with the support and collaboration of Ireland's
investment agency, IDA Ireland.
Micheál Martin,
Taoiseach, said: "I warmly welcome today's announcement from
AstraZeneca that it is to establish its first ever manufacturing
facility in Ireland. This $360 million investment represents a
significant commitment to Ireland and will see 100 jobs being
created. In choosing Ireland as the location for its
new next-generation active pharmaceutical ingredient
manufacturing facility, AstraZeneca joins the very strong and
successful network of global life sciences companies we have in
Ireland. I wish them every success with their operations
here."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "This is
a tremendously proud moment for us all at AstraZeneca and I am
delighted that we are bringing this very significant investment to
Dublin which, with the support of the IDA, will create highly
skilled jobs, nurture the country's dynamic life sciences sector
and allow for the development of high value-added
medicines."
Pam Cheng, Executive Vice President, Global Operations and IT,
said: "The future manufacturing of APIs for our medicines includes
compounds with highly complex synthesis, requiring next generation
technologies and capabilities that can respond quickly and nimbly
to rapidly-changing clinical and commercial needs. This
significant investment will ensure the AstraZeneca supply network
is fit for the future."
The investment programme is expected to significantly reduce
commercialisation lead times, costs and introduce more sustainable
manufacturing processes, contributing to the Company's Ambition
Zero Carbon programme. The industry-leading, future proof design of
the plant will permit the addition of capability to manufacture a
wide range of medicines, including new modalities such as antibody
drug conjugates and oligonucleotides.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
21 September 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|